P & G Health Ltd

When is the next results date for P & G Health Ltd?

No Upcoming Board Meetings

Who are in the management team of P & G Health Ltd?

As of June 2022, the management team of P & G Health Ltd includes Chairman S N Talwar, Managing Director Milind Thatte, CFO Amit Gupta, and several independent and executive directors, totaling ten members.

As of June 2022, the management team of P & G Health Ltd includes the following individuals:<BR><BR>1. S N Talwar - Chairman & Independent Director<BR>2. Rani A Jadhav - Independent Director<BR>3. Milind Thatte - Managing Director<BR>4. Amit Gupta - Director (Finance) & CFO<BR>5. Aalok Agrawal - Director<BR>6. Zeal Shah - Company Secretary & Compliance Officer<BR>7. Elizabeth Desmond - Director<BR>8. S Madhavan - Independent Director<BR>9. Lokesh Chandak - Executive Director<BR>10. Seema Sambasivan - Non-Executive Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and management of the company.

What does P & G Health Ltd do?

Procter & Gamble Health Ltd operates in the Pharmaceuticals & Biotechnology sector, focusing on health products. As of March 2025, it reported net sales of 311 Cr and a net profit of 61 Cr, with a market cap of Rs 9,243 Cr.

Overview:<BR>Procter & Gamble Health Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was originally incorporated as E Merck (India) Limited in 1967. It underwent a name change to Merck Limited on March 27, 2002, and was renamed Procter & Gamble Health Limited on May 6, 2019. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 311 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 61 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 9,243 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 35.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 2.51%<BR>- Debt Equity: -0.43<BR>- Return on Equity: 43.58%<BR>- Price to Book: 15.15<BR><BR>Contact Details:<BR>Address: Godrej One 8th Floor, Projshanagar Vikhroli (East) Mumbai Maharashtra : 400079<BR>Tel: 91-22-62109000<BR>Email: investorgrievance.im@pg.com<BR>Website: http://www.pghealthindia.com

Has P & G Health Ltd declared dividend?

Procter & Gamble Health Ltd has declared an 800% dividend, amounting to 80 per share, with an ex-date of February 21, 2025. The company has demonstrated strong total returns, particularly over longer periods, with a 44.84% return over the last 5 years.

Procter & Gamble Health Ltd has declared an 800% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 800%<BR>- Amount per share: 80<BR>- Ex-date: 21 Feb 25<BR><BR>Dividend Yield: 2.51%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 0.61%, the dividend return was 1.43%, resulting in a total return of 2.04%.<BR><BR>Over the past year, the price return stood at 12.45%, with a dividend return of 2.79%, leading to a total return of 15.24%.<BR><BR>For the 2-year period, the price return was 5.24%, the dividend return was 6.69%, culminating in a total return of 11.93%.<BR><BR>In the 3-year span, the price return reached 27.68%, the dividend return was 9.96%, resulting in a total return of 37.64%.<BR><BR>Over the last 4 years, the price return was -4.36%, while the dividend return was 9.08%, leading to a total return of 4.72%.<BR><BR>Finally, in the 5-year period, the price return was 30.81%, the dividend return was 14.03%, resulting in a total return of 44.84%.<BR><BR>Overall, Procter & Gamble Health Ltd has shown a strong dividend declaration alongside positive total returns, particularly in the longer-term periods, indicating a solid performance for investors.

Who are the peers of the P & G Health Ltd?

P & G Health Ltd's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Akums Drugs, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC. In terms of management risk, growth, and capital structure, Sun Pharma, Cipla, and Dr Reddy's Labs perform excellently, while P & G Health Ltd shows below-average growth and a 1-year return of 21.46%.

Peers: The peers of P & G Health Ltd are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Akums Drugs, Shilpa Medicare, Aarti Pharma, Strides Pharma, and FDC.<BR><BR>Quality Snapshot: Excellent management risk is observed at P & G Health Ltd, Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, while Average management risk is found at Akums Drugs, Shilpa Medicare, Aarti Pharma, and FDC. Below Average management risk is noted for Strides Pharma. In terms of Growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is reported for P & G Health Ltd, Divi's Lab., Torrent Pharma, Akums Drugs, Shilpa Medicare, Aarti Pharma, and Strides Pharma. Excellent capital structure is noted for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, P & G Health Ltd, and Aarti Pharma, while Good capital structure is observed at Torrent Pharma and Akums Drugs, and Below Average capital structure is found at Shilpa Medicare and Strides Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aarti Pharma at 58.00%, while the lowest is Akums Drugs, which has no available data. P & G Health Ltd's 1-year return is 21.46%, which is lower than Aarti Pharma's but higher than the returns of several other peers. Additionally, the six-month return is negative for Akums Drugs, Shilpa Medicare, Strides Pharma, and FDC.

Who are the top shareholders of the P & G Health Ltd?

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V. with 51.82%, mutual funds at 10.54%, foreign institutional investors at 6.87%, and Nippon Life India Trustee Ltd as the largest public shareholder at 4.1%. Individual investors collectively own 21.9% of the company.

The top shareholders of P & G Health Ltd include Procter And Gamble Overseas India B.V., which holds the largest stake at 51.82%. The company also has a diverse shareholder base, with mutual funds holding 10.54% across 11 schemes and foreign institutional investors (FIIs) holding 6.87% through 120 different entities. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 4.1%. Additionally, individual investors collectively own 21.9% of the company.

How big is P & G Health Ltd?

As of 24th July, Procter & Gamble Health Ltd has a market capitalization of 9,811.00 Cr, with recent net sales of 1,218.05 Cr and a net profit of 251.19 Cr.

As of 24th July, Procter & Gamble Health Ltd has a market capitalization of 9,811.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,218.05 Cr and a Net Profit of 251.19 Cr.<BR><BR>The latest reporting period for the balance sheet is June 2024, with Shareholder's Funds amounting to 538.24 Cr and Total Assets of 760.67 Cr.

Is P & G Health Ltd technically bullish or bearish?

As of October 6, 2025, the trend is mildly bullish due to daily moving averages and Bollinger Bands, but tempered by mildly bearish weekly MACD and KST indicators, suggesting a cautious bullish outlook.

As of 6 October 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a similar trend on both weekly and monthly time frames. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish sentiment. The Dow Theory also reflects a mildly bearish stance on the weekly chart, while remaining bullish on the monthly. Overall, the mixed signals suggest a cautious bullish outlook.

How has been the historical performance of P & G Health Ltd?

P & G Health Ltd experienced a decline in net sales and profitability in June 2024, with net sales at 1,151.26 Cr, down from 1,229.62 Cr in June 2023, and profit after tax decreasing to 200.98 Cr from 229.47 Cr. Overall, the company faced challenges with reduced sales, profits, and asset values.

Answer:<BR>The historical performance of P & G Health Ltd shows a fluctuating trend in net sales and profitability over the years. <BR><BR>Breakdown:<BR>In June 2024, P & G Health Ltd reported net sales of 1,151.26 Cr, a decrease from 1,229.62 Cr in June 2023, but an increase from 1,114.41 Cr in June 2022. The total operating income for June 2024 was 1,151.26 Cr, reflecting a similar trend. The company experienced a total expenditure of 845.26 Cr in June 2024, down from 904.94 Cr in June 2023, leading to an operating profit (PBDIT) of 321.63 Cr, which was lower than the 343.07 Cr reported in the previous year. Profit before tax also decreased to 273.32 Cr in June 2024 from 314.20 Cr in June 2023, resulting in a profit after tax of 200.98 Cr, down from 229.47 Cr. The earnings per share (EPS) for June 2024 was 121.07, a decline from 138.23 in June 2023. The company's total assets as of June 2024 were 760.67 Cr, down from 1,075.87 Cr in June 2023, while total liabilities decreased to 760.67 Cr from 1,075.87 Cr. Cash flow from operating activities was 228.00 Cr in June 2024, compared to 236.00 Cr in June 2023, indicating a slight decline in cash generation capabilities. Overall, the financial metrics indicate a challenging year for P & G Health Ltd, with declines in sales, profits, and asset values.

Should I buy, sell or hold Procter & Gamble Health Ltd?

Why is Procter & Gamble Health Ltd falling/rising?

As of 05-Feb, Procter & Gamble Health Ltd's stock price is slightly rising at 5,266.55, but it has shown a concerning long-term decline, down 9.79% over the past month and 7.62% year-to-date. Despite high management efficiency, poor growth metrics and reduced investor interest suggest a bearish trend.

As of 05-Feb, Procter & Gamble Health Ltd's stock price is experiencing a slight rise, currently at 5,266.55, with a change of 19.6 (0.37%) upward. However, despite this recent uptick, the stock has shown a concerning trend over longer periods. Over the past week, it has declined by 1.45%, and over the past month, it has fallen significantly by 9.79%. Year-to-date, the stock is down 7.62%, and it has underperformed against the benchmark Sensex, which has only decreased by 2.24% in the same timeframe.<BR><BR>The stock's performance today indicates it has outperformed its sector by 0.46%, but it is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a bearish trend in the stock's performance. Additionally, there is a notable decline in investor participation, with delivery volume dropping by 22.52% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>While the company boasts high management efficiency with a return on equity (ROE) of 36.14% and a low debt-to-equity ratio, these positives are overshadowed by poor long-term growth metrics, such as net sales growth of only 6.67% annually over the last five years. Furthermore, the stock has consistently underperformed against benchmarks, generating a return of -1.49% over the past year while its profits increased by 31.9%. This discrepancy is reflected in its high valuation metrics, including a price-to-book value of 14.1, which is considered expensive relative to its peers.<BR><BR>In summary, while there is a minor rise in the stock price today, the overall trend indicates a decline due to poor long-term growth prospects, reduced investor participation, and consistent underperformance against benchmarks.

Which are the latest news on P & G Health Ltd?

Are Procter & Gamble Health Ltd latest results good or bad?

Procter & Gamble Health Ltd's latest results show strong revenue growth with net sales up 15.06% quarter-on-quarter, but profitability has declined, with net profit down 12.37% from the previous quarter, raising concerns about operational efficiency and cost management. Overall, the results are mixed, indicating both positive revenue trends and troubling profit metrics.

Procter & Gamble Health Ltd's latest results present a mixed picture. On one hand, the company achieved a significant revenue increase, with net sales reaching ₹373.86 crores, which is a 15.06% increase quarter-on-quarter and a 20.69% increase year-on-year. This indicates strong demand for its products.<BR><BR>However, the profitability metrics are concerning. The net profit for Q3 FY26 was ₹77.59 crores, reflecting a decline of 12.37% from the previous quarter and a 14.60% drop compared to the same quarter last year. This decline in profit is attributed to margin compression and higher tax expenses, with the PAT margin falling to 20.75%, down 649 basis points from the previous quarter.<BR><BR>Additionally, the operating margin has also decreased significantly, indicating operational challenges that the company needs to address. Despite maintaining a strong return on equity of 49.51%, the overall financial performance suggests that while revenue growth is promising, the declining profits and margins raise concerns about the company's operational efficiency and cost management.<BR><BR>In summary, while the revenue growth is a positive sign, the decline in profitability and margins indicates that the latest results are not entirely favorable and warrant close attention from investors.